Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2004

View Archived Issues

Survivin promoter shown to be cancer-specific and may be effective in cancer gene therapy

AES-14 reduces severity and duration of OM in breast cancer patients receiving chemotherapy

Topiramate shows promise in the control of aggression

FDA approves Enablex for overactive bladder

Phase II study of p53 vaccine shows stabilization in patients with advanced breast cancer

European marketing approval for Kivexa

Novel 5-HMF prodrug prolongs antisickling effect in vivo

Enrollment completed in phase III studies of Oracea

Pegasys approved in Switzerland for chronic hepatitis B

Vicuron submits dalbavancin NDA

Additional phase II trial for INS-37217 Respiratory in cystic fibrosis

EMEA warns on coadministration of Reyataz and Norvir with omeprazole

Roche and BioTie collaborate on small-molecule VAP-1 inhibitor program

Animal results point to ATL-1102's potential in asthma

Octagam approved in Australia

Lumiliximab shows antitumor activity in patients with relapsed/refractory CLL

Phase II data on the effects and safety of AG-013736 monotherapy in AML and MDS

Clinical activity reported for MLN-518 in AML with ITD-mutated FLT3

Tapestry submits IND for novel taxane TPI-287

Abbott seeks approval of Humira for early RA in U.S. and Europe

EMEA warns on new safety findings for valdecoxib, parecoxib sodium

Reorganization of Astellas Group companies in Japan

Banyu describes compounds for the treatment of obesity

Agents for the treatment of diabetes claimed by Taisho

Amgen and Array BioPharma collaboration yields novel antiinflammatory agents

Scientists at 3-Dimensional report treatments for thrombosis-related disorders

DNA intercalating agents in early development at Cylene